We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

25 hedge funds and large institutions have $804K invested in Galmed Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

14% more funds holding

Funds holding: 22 → 25 (+3)

0% more ownership

Funds ownership: 0.06% → 0.06% (+0%)

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

53% less capital invested

Capital invested by funds: $1.7M → $804K (-$896K)

Holders
25
Holders Change
+3
Holders Change %
+13.64%
% of All Funds
0.43%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
6
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
+$10.7K
2
UBS Group
UBS Group
Switzerland
+$9.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$9.04K
4
TSS
Two Sigma Securities
New York
+$8.79K
5
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$6.74K

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$19.5K
2
Citigroup
Citigroup
New York
-$3K
3
Morgan Stanley
Morgan Stanley
New York
-$2.9K
4
RJFSA
Raymond James Financial Services Advisors
Florida
-$2.82K
5
Millennium Management
Millennium Management
New York
-$1.88K
Name Holding Trade Value Shares
Change 		Change in
Stake
BI
1
BVF Inc
California
$558K – – –
Morgan Stanley
2
Morgan Stanley
New York
$59K -$2.9K -34 -3%
RJA
3
Raymond James & Associates
Florida
$49K -$768 -9 -1%
WWM
4
Western Wealth Management
Colorado
$19K – – –
RJFSA
5
Raymond James Financial Services Advisors
Florida
$18K -$2.82K -33 -9%
Renaissance Technologies
6
Renaissance Technologies
New York
$16K +$9.04K +106 +60%
Millennium Management
7
Millennium Management
New York
$15K -$1.88K -22 -8%
Cambridge Investment Research Advisors
8
Cambridge Investment Research Advisors
Iowa
$11K +$3.75K +44 +29%
Geode Capital Management
9
Geode Capital Management
Massachusetts
$8K – – –
UBS Group
10
UBS Group
Switzerland
$8K +$9.9K +116 +341%
VF
11
Virtu Financial
New York
$7K +$10.7K +125 New
Citadel Advisors
12
Citadel Advisors
Florida
$6K -$19.5K -228 -69%
TSS
13
Two Sigma Securities
New York
$6K +$8.79K +103 New
BNP Paribas Financial Markets
14
BNP Paribas Financial Markets
France
$4.45K +$6.74K +79 New
BAM
15
Brave Asset Management
New Jersey
$4K – – –
GSC
16
Ground Swell Capital
South Carolina
$4K +$6.14K +72 New
Jane Street
17
Jane Street
New York
$4K +$6.57K +77 New
Susquehanna International Group
18
Susquehanna International Group
Pennsylvania
$3K – – –
Wells Fargo
19
Wells Fargo
California
$1K -$1.02K -12 -34%
Group One Trading
20
Group One Trading
Illinois
$1K – – –
TFGT
21
TS Financial Group (TSFG)
Illinois
$1K – – –
FDCDDQ
22
Federation des caisses Desjardins du Quebec
Quebec, Canada
$778 – – –
TWC
23
TD Waterhouse Canada
Ontario, Canada
$423 – – –
Citigroup
24
Citigroup
New York
– -$3K -21 Closed
Simplex Trading
25
Simplex Trading
Illinois
– -$1K -15 Closed

GLMD Hedge Fund Activity: Q3 2022 in Review

25 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q3 2022, worth a combined $804K — down 53% from $1.7M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new GLMD positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 6 trimmed.

The largest buyer was Virtu Financial, opening a new position worth an estimated $10.7K. The largest seller was Citadel Advisors, cutting an estimated $19.5K.

  • 25 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q3 2022, up from 22 in Q2 2022.
  • Funds reported $804K of Galmed Pharmaceuticals stock for Q3 2022, down 53% quarter-over-quarter.
  • 5 funds opened new Galmed Pharmaceuticals positions in Q3 2022 and 2 closed out, a net change of +3 holders.
  • The largest Galmed Pharmaceuticals buyer in Q3 2022 was Virtu Financial, an estimated $10.7K added.
  • The largest Galmed Pharmaceuticals seller in Q3 2022 was Citadel Advisors, an estimated $19.5K sold.

Based on aggregated 13F filings for Q3 2022.